期刊
CELL
卷 174, 期 4, 页码 938-+出版社
CELL PRESS
DOI: 10.1016/j.cell.2018.07.033
关键词
-
资金
- Centers of Excellence in Translational Research Award of NIAID [U19 AI109762]
- NIAID [HHSN272201400058C, U19AI135995]
- Human Therapeutic Monoclonal Antibodies Platform [IAF311007]
Antibodies are promising post-exposure therapies against emerging viruses, but which antibody features and in vitro assays best forecast protection are unclear. Our international consortium systematically evaluated antibodies against Ebola virus (EBOV) using multidisciplinary assays. For each antibody, we evaluated epitopes recognized on the viral surface glycoprotein (GP) and Secreted glycoprotein (sGP), readouts of multiple neutralization assays, fraction of virions left un-neutralized, glycan structures,phagocytic and natural killer cell functions elicited, and in vivo protection in a mouse challenge model. Neutralization and induction of multiple immune effector functions (IEFs) correlated most strongly with protection. Neutralization predominantly occurred via epitopes maintained on endosomally cleaved GP, whereas maximal IEF mapped to epitopes farthest from the viral membrane. Unex-pectedly, sGP cross-reactivity did not significantly influence in vivo protection. This comprehensive dataset and vaccine responses and a roadmap for therapeutic development for EBOV and related viruses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据